The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical)
- PMID: 37062817
- DOI: 10.1089/jir.2022.0185
The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical)
Abstract
Cytokine storm refers to the overproduction of immune and inflammatory cells and their proteins (cytokines) [interleukin (IL)-1 and IL-6] causing acute respiratory distress syndrome in COVID-19. COVID-19 causes inflammatory reactions, and patients with COVID-19 had categorized as mild, severe, and critical after reviewing previous studies. Then, it is crucial to find immune-inflammatory indicators that might predict the disorder severity and the prognosis primarily for guiding medical therapy in the face of this unexpectedly developing unique infectious disease. Higher levels of IL-6 and IL-1 levels might be seen in patients with COVID-19 at each stage. In addition, IL-1-induced IL-6 assists in the synthesis of liver C-reactive protein (CRP) in acute phase responses. Recent studies suggested that IL-6 levels are an independent predictor of COVID-19 illness because they were significantly higher in patients with severe than with mild COVID-19 symptoms. Anakinra and tocilizumab (TCZ) are beneficial in lowing mortality in COVID-19 patients; however, information on their safety and efficacy is scarce. The aim of this study was to investigate the role of inflammatory cytokines (IL-1 and IL-6) as potential biomarkers in the different stages (mild, severe, and critical) of COVID-19. A systematic search during the years 2021-2022 using the keywords SARS-CoV-2, COVID-19, IL-6, IL-1, CRP, mild stage, severe stage, critical stage, cytokine storm, tocilizumab, and anakinra was performed in PubMed and Google Scholar databases. This study reviews studies that have investigated the role of high levels of these cytokines in the severity of the disease in patients with COVID-19 and the inhibitory function of TCZ and anakinra in preventing mechanical ventilation and patient mortality. According to the result, studies suggest that decreased innate immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in association with the production of inflammatory cytokines is the determining and driving function of COVID-19.
Keywords: COVID-19; CRP cytokine storm; IL-1; IL-6; SARS-CoV-2; anakinra; tocilizumab.
Similar articles
-
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5. Trials. 2020. PMID: 32493441 Free PMC article.
-
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.J Autoimmun. 2020 Dec;115:102537. doi: 10.1016/j.jaut.2020.102537. Epub 2020 Aug 20. J Autoimmun. 2020. PMID: 32843231 Free PMC article.
-
Current evidence on the use of anakinra in COVID-19.Int Immunopharmacol. 2022 Oct;111:109075. doi: 10.1016/j.intimp.2022.109075. Epub 2022 Jul 20. Int Immunopharmacol. 2022. PMID: 35905562 Free PMC article. Review.
-
Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129. Emerg Microbes Infect. 2020. PMID: 32475230 Free PMC article.
-
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9. J Med Virol. 2020. PMID: 32436994 Free PMC article.
Cited by
-
Exploring the viability of Zeatin as a prospective therapeutic candidate for investigating the complex interplay between severe acute respiratory syndrome coronavirus (SARS-CoV) and Alzheimer's disease.In Silico Pharmacol. 2024 Mar 28;12(1):21. doi: 10.1007/s40203-024-00195-3. eCollection 2024. In Silico Pharmacol. 2024. PMID: 38559708 Free PMC article.
-
Estimating the prevalence of persistent symptoms after SARS-CoV-2 infection (post-COVID-19 syndrome): a regional cross-sectional study protocol.BMJ Open. 2025 May 30;15(5):e093844. doi: 10.1136/bmjopen-2024-093844. BMJ Open. 2025. PMID: 40447416 Free PMC article.
-
Questionnaire survey of risk factors for recurrence of ocular inflammation in patients with uveitis after SARS-CoV-2 infection.Front Cell Infect Microbiol. 2024 Jan 30;13:1291991. doi: 10.3389/fcimb.2023.1291991. eCollection 2023. Front Cell Infect Microbiol. 2024. PMID: 38351911 Free PMC article.
-
Aggregate Index of Systemic Inflammation (AISI), Disease Severity, and Mortality in COVID-19: A Systematic Review and Meta-Analysis.J Clin Med. 2023 Jul 10;12(14):4584. doi: 10.3390/jcm12144584. J Clin Med. 2023. PMID: 37510699 Free PMC article. Review.
-
Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies.Viruses. 2024 Nov 21;16(12):1811. doi: 10.3390/v16121811. Viruses. 2024. PMID: 39772122 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous